Tafasitamab
Tafasitamab, sold under the brand name Monjuvi, is a medication used in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).[1]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | CD19 |
Clinical data | |
Trade names | Monjuvi |
Other names | tafasitamab-cxix, MOR208, Xmab5574 |
AHFS/Drugs.com | Monjuvi |
License data |
|
Routes of administration | Intravenous |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6550H10092N1724O2048S52 |
Molar mass | 147425.93 g·mol−1 |
Tafasitamab is a humanized Fc-modified cytolytic CD19 antibody.[1][2]
Tafasitamab was approved for medical use in the United States in July 2020.[3][2]
Medical uses
Tafasitamab, in combination with lenalidomide, is indicated for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).[1]
Society and culture
Names
Tafasitamab is the international nonproprietary name (INN).[4]
gollark: Maybe all particles on SC are just generated by a lone, overtaxed turtle.
gollark: Buy Ender Particle turtles for just 7KST extra with your order of a Synthetic Dragon Egg!
gollark: Well, *that* makes *much* more sense...
gollark: Madness.
gollark: If it makes particles, how craft?
References
- "Monjuvi (tafasitamab-cxix) for injection, for intravenous use" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 31 July 2020.
- "FDA Approves Monjuvi (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)" (Press release). MorphoSys AG. 31 July 2020. Retrieved 31 July 2020 – via Business Wire.
- "Monjuvi: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 31 July 2020.
- World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1): 118–9. hdl:10665/330896. License: CC BY-NC-SA 3.0 IGO.
External links
- "Tafasitamab". Drug Information Portal. U.S. National Library of Medicine.
- "MOR208 (tafasitamab)". MorphoSys AG.
- Clinical trial number NCT02399085 for "A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL (L-MIND)" at ClinicalTrials.gov
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.